CA2773611A1 - Use of guaifenesin for inhibiting mucin secretion - Google Patents
Use of guaifenesin for inhibiting mucin secretion Download PDFInfo
- Publication number
- CA2773611A1 CA2773611A1 CA2773611A CA2773611A CA2773611A1 CA 2773611 A1 CA2773611 A1 CA 2773611A1 CA 2773611 A CA2773611 A CA 2773611A CA 2773611 A CA2773611 A CA 2773611A CA 2773611 A1 CA2773611 A1 CA 2773611A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- guaifenesin
- administering
- effective amount
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 229960002146 guaifenesin Drugs 0.000 title claims abstract description 29
- 230000028327 secretion Effects 0.000 title claims abstract description 28
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 5
- 108010063954 Mucins Proteins 0.000 title claims description 11
- 102000015728 Mucins Human genes 0.000 title claims description 11
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 210000003097 mucus Anatomy 0.000 claims abstract description 23
- 239000007788 liquid Substances 0.000 claims description 7
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 230000001387 anti-histamine Effects 0.000 claims description 5
- 239000000739 antihistaminic agent Substances 0.000 claims description 5
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 5
- 239000000850 decongestant Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 claims description 3
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229960005008 doxylamine succinate Drugs 0.000 claims description 3
- 229960002179 ephedrine Drugs 0.000 claims description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229960003910 promethazine Drugs 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 230000000954 anitussive effect Effects 0.000 claims 4
- 229940124584 antitussives Drugs 0.000 claims 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 4
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 claims 2
- JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 claims 2
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 claims 2
- ZZYHCCDMBJTROG-UHFFFAOYSA-N 2-(2-benzylphenoxy)ethyl-dimethylazanium;3-carboxy-3,5-dihydroxy-5-oxopentanoate Chemical compound OC(=O)CC(O)(C(O)=O)CC([O-])=O.C[NH+](C)CCOC1=CC=CC=C1CC1=CC=CC=C1 ZZYHCCDMBJTROG-UHFFFAOYSA-N 0.000 claims 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims 2
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 claims 2
- 229960003108 brompheniramine maleate Drugs 0.000 claims 2
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 claims 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims 2
- 229960002881 clemastine Drugs 0.000 claims 2
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims 2
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 claims 2
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 claims 2
- 229960003592 fexofenadine Drugs 0.000 claims 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 claims 2
- 229960002254 phenyltoloxamine citrate Drugs 0.000 claims 2
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 claims 2
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 claims 2
- 229940018203 pyrilamine maleate Drugs 0.000 claims 2
- WFXURHIXPXVPGM-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 WFXURHIXPXVPGM-UHFFFAOYSA-N 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 229960003956 phenindamine tartrate Drugs 0.000 claims 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 claims 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 description 3
- 102100022496 Mucin-5AC Human genes 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001886 ciliary effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003534 oscillatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- GXMBHQRROXQUJS-UHFFFAOYSA-N (2-hept-2-ynylsulfanylphenyl) acetate Chemical compound CCCCC#CCSC1=CC=CC=C1OC(C)=O GXMBHQRROXQUJS-UHFFFAOYSA-N 0.000 description 1
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
- 101150039167 Bex3 gene Proteins 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000795424 Epia Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 101150109842 GUA1 gene Proteins 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 101100496087 Mus musculus Clec12a gene Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 231100000480 WST assay Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940070335 chlor-phen Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- MEFOUWRMVYJCQC-UHFFFAOYSA-N rimsulfuron Chemical compound CCS(=O)(=O)C1=CC=CN=C1S(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 MEFOUWRMVYJCQC-UHFFFAOYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 210000004878 submucosal gland Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/558,517 US20110065744A1 (en) | 2009-09-12 | 2009-09-12 | Method Of Inhibiting Mucin Secretion |
| US12/558,517 | 2009-09-12 | ||
| GB1002039.4 | 2010-02-09 | ||
| GBGB1002039.4A GB201002039D0 (en) | 2010-02-09 | 2010-02-09 | Method of inhibiting mucin secretion |
| PCT/GB2010/051525 WO2011030163A1 (en) | 2009-09-12 | 2010-09-13 | Use of guaifenesin for inhibiting mucin secretion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2773611A1 true CA2773611A1 (en) | 2011-03-17 |
Family
ID=42941393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2773611A Abandoned CA2773611A1 (en) | 2009-09-12 | 2010-09-13 | Use of guaifenesin for inhibiting mucin secretion |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2475360A1 (enExample) |
| JP (1) | JP2013504554A (enExample) |
| KR (1) | KR20120068889A (enExample) |
| CN (1) | CN102596189A (enExample) |
| AU (1) | AU2010294008B2 (enExample) |
| BR (1) | BR112012005517A2 (enExample) |
| CA (1) | CA2773611A1 (enExample) |
| MX (1) | MX2012003042A (enExample) |
| MY (1) | MY161187A (enExample) |
| RU (1) | RU2012114323A (enExample) |
| WO (1) | WO2011030163A1 (enExample) |
| ZA (1) | ZA201201822B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1206995A1 (en) * | 2012-04-06 | 2016-01-22 | The Uab Research Foundation | Methods for increasing cftr activity |
| KR102211605B1 (ko) * | 2018-02-26 | 2021-02-04 | 대한민국 | 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA963590B (en) * | 1995-05-10 | 1996-11-19 | Adcock Ingram Ltd | Pharmaceutical composition |
| US6846799B1 (en) * | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| EP1471872A2 (en) * | 2002-02-04 | 2004-11-03 | Pharmacia Corporation | Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof |
| CN1835942A (zh) * | 2003-06-19 | 2006-09-20 | 金纳莱公司 | 粘蛋白合成抑制剂 |
| US20050095288A1 (en) * | 2003-11-03 | 2005-05-05 | Andrx Labs, Llc | Decongestant and expectorant tablets |
| US20050266032A1 (en) * | 2003-12-17 | 2005-12-01 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing multiple drugs |
| US20080014261A1 (en) * | 2006-07-12 | 2008-01-17 | Giordano John A | Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction |
| US20090202633A1 (en) * | 2008-01-03 | 2009-08-13 | Siva Ramakrishna Velaga | Extended release formulations of guaifenesin |
-
2010
- 2010-09-13 BR BR112012005517A patent/BR112012005517A2/pt not_active Application Discontinuation
- 2010-09-13 MY MYPI2012001112A patent/MY161187A/en unknown
- 2010-09-13 CA CA2773611A patent/CA2773611A1/en not_active Abandoned
- 2010-09-13 AU AU2010294008A patent/AU2010294008B2/en not_active Ceased
- 2010-09-13 CN CN2010800492171A patent/CN102596189A/zh active Pending
- 2010-09-13 WO PCT/GB2010/051525 patent/WO2011030163A1/en not_active Ceased
- 2010-09-13 MX MX2012003042A patent/MX2012003042A/es unknown
- 2010-09-13 RU RU2012114323/15A patent/RU2012114323A/ru unknown
- 2010-09-13 EP EP10757117A patent/EP2475360A1/en not_active Ceased
- 2010-09-13 KR KR1020127007996A patent/KR20120068889A/ko not_active Withdrawn
- 2010-09-13 JP JP2012528455A patent/JP2013504554A/ja active Pending
-
2012
- 2012-03-13 ZA ZA2012/01822A patent/ZA201201822B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011030163A1 (en) | 2011-03-17 |
| ZA201201822B (en) | 2013-05-29 |
| CN102596189A (zh) | 2012-07-18 |
| AU2010294008B2 (en) | 2014-08-14 |
| MY161187A (en) | 2017-04-14 |
| BR112012005517A2 (pt) | 2016-04-19 |
| MX2012003042A (es) | 2012-05-29 |
| KR20120068889A (ko) | 2012-06-27 |
| AU2010294008A1 (en) | 2012-04-05 |
| EP2475360A1 (en) | 2012-07-18 |
| JP2013504554A (ja) | 2013-02-07 |
| RU2012114323A (ru) | 2013-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weidner et al. | Potassium paraaminobenzoate (POTABA™) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study | |
| US8865641B2 (en) | Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways | |
| Wu et al. | Paeoniflorin confers ferroptosis resistance by regulating the gut microbiota and its metabolites in diabetic cardiomyopathy | |
| Wen et al. | Denatonium inhibits growth and induces apoptosis of airway epithelial cells through mitochondrial signaling pathways | |
| Shuangshuang et al. | Maimendong decoction regulates M2 macrophage polarization to suppress pulmonary fibrosis via PI3K/Akt/FOXO3a signalling pathway-mediated fibroblast activation | |
| JP2024543419A (ja) | Ｓｓａｏ阻害剤による肝障害の治療 | |
| CA2773611A1 (en) | Use of guaifenesin for inhibiting mucin secretion | |
| Malo et al. | The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis | |
| Mekala et al. | Alcohol and e-cigarette damage alveolar-epithelial barrier by activation of P2X7r and provoke brain endothelial injury via extracellular vesicles | |
| Asifali et al. | Frequency and clinical presentation of oral submucous fibrosis | |
| TW201609111A (zh) | 人參皂苷ｍ１用於抑制腎纖維化之用途 | |
| Shih et al. | Effect ofAnoectochilus formosanuson fibrosis and regeneration of the liver in rats. | |
| Namba et al. | Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes | |
| Selman et al. | Lung collagen metabolism and the clinical course of hypersensitivity pneumonitis | |
| Mattoli et al. | Nedocromil sodium prevents the release of 15-hydroxyeicosatetraenoic acid from human bronchial epithelial cells exposed to toluene diisocyanate in vitro | |
| Herrmann et al. | Type III collagen aminopropeptide and laminin PI levels in serum of patients with silicosis‐associated and idiopathic systemic scleroderma | |
| US20110065744A1 (en) | Method Of Inhibiting Mucin Secretion | |
| EP3863643A1 (en) | Azd3355 (lesogaberan) for treatment and prevention of nonalcoholic steatohepatitis (nash), liver fibrosis, and other liver conditions | |
| Kulkarni et al. | Correlation between hypothyroidism and gallstone disease in central India | |
| UA47505C2 (uk) | Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну | |
| US20240295566A1 (en) | Method for diagnosing and treating metabolic disorders | |
| Maritzen et al. | ClC-5 does not affect megalin expression and function in the thyroid | |
| EP4523754A2 (en) | Improved administration of glycylcyclines | |
| Hisamatsu et al. | Effect of leukotriene C4 exposure on ciliated cells of the nasal mucosa | |
| CN113874006A (zh) | 使用左旋（R）β2受体激动剂在预防和治疗肺部炎症与重构及减少其毒副作用的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150820 |
|
| FZDE | Discontinued |
Effective date: 20190514 |